retatrutide eli lilly press release 2024 2025 Lilly's triple-acting obesity drug hits goal in Phase 3 trial Eli Lilly's retatrutide shows promising
Description
Probst L., Monnerat S., Vogt D
A direct head-to-head trial (NCT06662383, 800 patients) is underway with results in December 2026
If youre deciding between different protein options, this whey protein vs
The information presented on this site is for educational purposes only and is not intended to replace advice from your physician or other health care professional or any information found on any product label or packaging
"Total annual revenue has the potential to reach $400 billion in a scenario where all 23 upcoming studies are successful," Goldman said
